Abstract
Objective Lactoferrin (LF) is effective in the prevention of sepsis in very low birth weight
(VLBW) neonates. T-regulatory cells (Tregs) are important subsets of T lymphocytes
that control pathogen-specific immune responses and are essential for intestinal immune
homoeostasis. The aim of the present study is to determine whether oral LF at a dosage
of 200 mg/d reduces nosocomial sepsis episodes and necrotizing enterocolitis (NEC)
in premature infants and to evaluate the possible effects of LF on Treg levels.
Study Design In this prospective, placebo-controlled, double-blind, randomized trial, infants
either VLBW or born before 32 weeks were assigned to receive either placebo (n = 25), or 200 mg LF (n = 25) daily throughout hospitalization. Episodes of culture proven nosocomial sepsis
and NEC were recorded. The level of FOXP3 + CD4 + CD25hi lymphocytes was studied by
flow cytometry at birth and discharge. A third comparison was made with healthy term
neonates (n = 16).
Results Fewer sepsis episodes were observed in LF-treated infants (4.4 vs. 17.3/1,000 patient
days, p = 0.007) with none developing NEC, without statistical significance. Treg levels
at birth and discharge were similar, while preterm infants showed significantly lower
levels than term controls. However, individual increases in Treg levels were higher
in the LF group.
Conclusion LF prophylaxis reduced nosocomial sepsis episodes. Treg levels in preterm infants
were lower than in term infants and an increase of Treg levels under LF prophylaxis
was observed. Increase in Treg levels can be the mechanism for protective effects
of LF on nosocomial sepsis.
Keywords
lactoferrin - VLBW - sepsis - NEC - T-regulatory lymphocytes